Back

Bukwang Pharmaceutical sales rise 15.9% as Latuda reaches No. 3

Verifying
  • Bukwang Pharmaceutical recorded 104.8 billion Korean won in first-half consolidated sales.
  • Latuda generated 7.04 billion Korean won, becoming the company’s third-highest-selling product.
  • Bukwang plans a phase 3 trial for Latuda’s major depressive disorder indication.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.